DBV Technologies (NASDAQ:DBVT) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of DBV Technologies (NASDAQ:DBVT) from a strong sell rating to a hold rating in a research note released on Monday,Zacks.com reports.

A number of other equities research analysts also recently commented on the company. Lifesci Capital upgraded DBV Technologies to a “strong-buy” rating in a research report on Thursday, June 26th. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. Finally, JMP Securities reissued a “market outperform” rating and issued a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.75.

DBV Technologies Trading Up 9.4%

NASDAQ:DBVT opened at $10.00 on Monday. The company has a 50-day moving average of $9.55 and a 200-day moving average of $8.94. The firm has a market cap of $273.95 million, a price-to-earnings ratio of -2.10 and a beta of -0.36. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. On average, research analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DBVT. Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies in the 2nd quarter worth about $340,000. Octagon Capital Advisors LP acquired a new position in shares of DBV Technologies in the 2nd quarter valued at about $9,315,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the second quarter worth approximately $9,649,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the second quarter worth approximately $9,659,000. Finally, Vivo Capital LLC acquired a new stake in shares of DBV Technologies during the second quarter worth approximately $9,659,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.